Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Cancer Vaccines
  • Genes, ras
  • Mutation
  • Pancreatectomy
  • Pancreatic Neoplasms

abstract

  • K-ras vaccination for patients with resectable pancreatic adenocarcinoma proved to be safe and tolerable with however no elicitable immunogenicity and unproven efficacy. Future development of adjuvant vaccine therapies should use more immunogenic vaccines.

publication date

  • June 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/COC.0b013e3181e84b1f

PubMed ID

  • 20686403

Additional Document Info

start page

  • 321

end page

  • 5

volume

  • 34

number

  • 3